Milestone Pharmaceuticals Inc (MIST)

Apr 09, 2025

Milestone Pharmaceuticals: A Golden Opportunity To Buy On Etripamil's CRL In PSVT - Seeking Alpha

Apr 09, 2025

Apr 05, 2025

Research Analysts Set Expectations for MIST Q1 Earnings - Defense World

Apr 05, 2025

Apr 05, 2025

MIST stock touches 52-week low at $0.7 amid market challenges - Investing.com Canada

Apr 05, 2025

Apr 04, 2025

MIST Stock Falls 66% Following Complete Response Letter for Cardamyst - MSN

Apr 04, 2025

Apr 04, 2025

MIST stock touches 52-week low at $0.7 amid market challenges By Investing.com - Investing.com South Africa

Apr 04, 2025

Apr 04, 2025

Milestone Pharmaceuticals (NASDAQ:MIST) Cut to Hold at TD Cowen - Defense World

Apr 04, 2025

Apr 02, 2025

Milestone Pharmaceuticals downgraded to Hold from Buy at TD Cowen - Yahoo Finance

Apr 02, 2025

Apr 02, 2025

Milestone Pharmaceuticals (NASDAQ:MIST) Downgraded by TD Securities to Hold - Defense World

Apr 02, 2025

Apr 01, 2025

TD downgrades Milestone Pharmaceuticals, suspends target on Etripamil uncertainty By Investing.com - Investing.com South Africa

Apr 01, 2025

Apr 01, 2025

HC Wainwright Adjusts Price Target on Milestone Pharmaceuticals to $10 From $25, Maintains Buy Rating - MarketScreener

Apr 01, 2025

Apr 01, 2025

Milestone Pharmaceuticals price target lowered to $10 from $25 at H.C. Wainwright - TipRanks

Apr 01, 2025

Apr 01, 2025

TD Cowen Downgrades Milestone Pharmaceuticals to Hold From Buy - MarketScreener

Apr 01, 2025

Apr 01, 2025

Milestone Pharmaceuticals stock rating cut to hold by TD Cowen - Investing.com India

Apr 01, 2025

Mar 31, 2025

Milestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray – But Reta - Asianet Newsable

Mar 31, 2025

Mar 30, 2025

HC Wainwright Reaffirms “Buy” Rating for Milestone Pharmaceuticals (NASDAQ:MIST) - Defense World

Mar 30, 2025

Mar 29, 2025

Milestone CRL affirms integrity of clinical data, says H.C. Wainwright - Yahoo Finance

Mar 29, 2025

Mar 28, 2025

Milestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray – But Retail’s Positive - NewsBreak: Local News & Alerts

Mar 28, 2025

Mar 28, 2025

Sector Update: Health Care Stocks Mixed Friday Afternoon - TradingView

Mar 28, 2025

Mar 28, 2025

Sector Update: Health Care - TradingView

Mar 28, 2025

Mar 28, 2025

US FDA declines to approve Milestone's heart rhythm nasal spray; shares halve - Reuters

Mar 28, 2025

Mar 28, 2025

Milestone Pharmaceuticals: Buy Rating Affirmed Despite CARDAMYST Approval Delay, Strong Market Potential and Robust Financial Position - TipRanks

Mar 28, 2025

Mar 28, 2025

Milestone Pharmaceuticals (MIST) Receives FDA Response on Etripa - GuruFocus

Mar 28, 2025

Mar 28, 2025

Milestone flagging following CRL - The Pharma Letter

Mar 28, 2025

Mar 28, 2025

Piper Sandler Adjusts Price Target on Milestone Pharmaceuticals to $4 From $5, Maintains Overweight Rating - Marketscreener.com

Mar 28, 2025

Mar 28, 2025

Milestone Pharma says FDA declined to approve heart disorder therapy - MSN

Mar 28, 2025

Mar 28, 2025

Milestone Pharmaceuticals Says FDA Cites Manufacturing Concerns for Etripamil NDA; Shares Fall - Marketscreener.com

Mar 28, 2025

Mar 28, 2025

FDA Declines Milestone Pharmaceuticals' (MIST) Heart Drug Approval - GuruFocus

Mar 28, 2025

Mar 28, 2025

Manufacturing issues trip up Milestone's long-awaited FDA landmark - FiercePharma

Mar 28, 2025

Mar 28, 2025

Milestone Pharma stock in focus after FDA snub (MIST:NASDAQ) - Seeking Alpha

Mar 28, 2025

Mar 28, 2025

FDA flags issues with Milestone’s new drug application By Investing.com - Investing.com South Africa

Mar 28, 2025

Mar 28, 2025

FDA Issues Complete Response Letter For Etripamil For PSVT - Marketscreener.com

Mar 28, 2025

Mar 28, 2025

Milestone Pharma slumps after FDA declines to approve heart rhythm nasal spray - TradingView

Mar 28, 2025

Mar 28, 2025

FDA flags issues with Milestone’s new drug application - Investing.com India

Mar 28, 2025

Mar 28, 2025

Milestone Pharmaceuticals announces FDA issued CRL for etripamil - TipRanks

Mar 28, 2025

Mar 28, 2025

US FDA declines to approve Milestone's heart rhythm nasal spray - MarketScreener

Mar 28, 2025

Mar 28, 2025

FDA Issues Complete Response Letter for Etripamil for PSVT - The Manila Times

Mar 28, 2025

Mar 28, 2025

US FDA declines to approve Milestone Pharma's heart rhythm nasal spray - Marketscreener.com

Mar 28, 2025

Mar 28, 2025

Milestone Pharmaceuticals Inc. Announces FDA Issues Complete Response Letter for Etripamil for PSVT - MarketScreener

Mar 28, 2025

Mar 27, 2025

Milestone Pharmaceuticals Stock on the Rise: What’s Next? - timothysykes.com

Mar 27, 2025

Mar 26, 2025

Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment - GlobeNewswire

Mar 26, 2025

Mar 26, 2025

Major PTSD Treatment Advance: FDA Fast-Track Path Opens for Revolutionary Drug SPC-15 - Stock Titan

Mar 26, 2025

Mar 21, 2025

Milestone Pharmaceuticals: A Compelling Value Proposition For Patients And Payers - Seeking Alpha

Mar 21, 2025

Mar 21, 2025

HC Wainwright Brokers Decrease Earnings Estimates for MIST - Defense World

Mar 21, 2025

Mar 20, 2025

Milestone Pharmaceuticals to present clinical data on etripamil - TipRanks

Mar 20, 2025